T helper 2 cell–directed immunotherapy eliminates precancerous skin lesions
Journal of Clinical Investigation · 02.01.2025 · 135 (1)
DOI: 10.1172/jci183274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.01.2025. Verfasst von Tomonori Oka und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Immunology and Cutaneous Biology Research Center, Krantz Family Center for Cancer Research and Department of Dermatology, Massachus…. Hauptthemen laut MEDLINE: Skin Neoplasms, Th2 Cells, Precancerous Conditions, Calcitriol. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAMS NIH HHS, Burroughs Wellcome Fund.
Abstract (Originalsprache)
The continuous rise in skin cancer incidence highlights an imperative for improved skin cancer prevention. Topical calcipotriol-plus–5-fluorouracil (calcipotriol-plus–5-FU) immunotherapy effectively eliminates precancerous skin lesions and prevents squamous cell carcinoma (SCC) in patients. However, its mechanism of action remains unclear. Herein, we demonstrate that calcipotriol-plus–5-FU immunotherapy induces T helper type 2 (Th2) immunity, eliminating premalignant keratinocytes in humans. CD4 + Th2 cells were required and were sufficient downstream of thymic stromal lymphopoietin cytokine induction by calcipotriol to suppress skin cancer development. Th2-associated cytokines induced IL-24 expression in cancer cells, resulting in toxic autophagy and anoikis followed by apoptosis. Calcipotriol-plus–5-FU immunotherapy was dependent on IL-24 to suppress skin carcinogenesis in vivo. Collectively, our findings establish a critical role for Th2 immunity in cancer immunoprevention and highlight the Th2/IL-24 axis as an innovative target for skin cancer prevention and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer Immunology and Cutaneous Biology Research Center, Krantz Family Center for Cancer Research and Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
- VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
- VCU Massey Comprehensive Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
- Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Förderung
- NCI NIH HHS
- NIAMS NIH HHS
- Burroughs Wellcome Fund
- LEO Fondet
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Cancer Institute
Zitieren
APA
Oka, T., Smith, S. S., Son, H. G., Lee, T., Oliver-Garcia, V. S., Mortaja, M., Trerice, K. E., Isakoff, L. S., Conrad, D. N., Azin, M., Raval, N. S., Tabacchi, M., Emdad, L., Das, S. K., Fisher, P. B., Cornelius, L. A., & Demehri, S. (2025). T helper 2 cell–directed immunotherapy eliminates precancerous skin lesions. Journal of Clinical Investigation, 135(1). https://doi.org/10.1172/jci183274
Vancouver
Oka T, Smith SS, Son HG, Lee T, Oliver-Garcia VS, Mortaja M, et al. T helper 2 cell–directed immunotherapy eliminates precancerous skin lesions. Journal of Clinical Investigation. 2025;135(1). doi:10.1172/jci183274
BibTeX
@article{Oka2025,
author = {Oka, Tomonori and Smith, Sabrina S and Son, Heehwa G and Lee, Truelian and Oliver-Garcia, Valeria S and Mortaja, Mahsa and Trerice, Kathryn E and Isakoff, Lily S and Conrad, Danielle N and Azin, Marjan and Raval, Neel S and Tabacchi, Mary and Emdad, Luni and Das, Swadesh K and Fisher, Paul B and Cornelius, Lynn A and Demehri, Shadmehr},
title = {T helper 2 cell–directed immunotherapy eliminates precancerous skin lesions},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {1},
doi = {10.1172/jci183274}
}
EUVIMED